The FDA has revised its 2016 draft guidance on charging patients for drugs under investigational new drug applications (IND) in clinical trials or expanded access programs. The updates, which pertain mostly to expanded access, include additional recommendations on distributing first year costs and submitting statements from independent accountants.
Source: Drug Industry Daily